Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

NCT01996865 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01996865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01996865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2014
Completion date
September 17, 2024
Enrollment
503 (actual)
Sites
126

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin